nodes	percent_of_prediction	percent_of_DWPC	metapath
Valrubicin—urinary bladder cancer—prostate cancer	0.237	1	CtDrD
Valrubicin—Epirubicin—prostate cancer	0.152	0.519	CrCtD
Valrubicin—Doxorubicin—prostate cancer	0.14	0.481	CrCtD
Valrubicin—TOP2A—prostate cancer	0.125	1	CbGaD
Valrubicin—TOP2A—Mitoxantrone—prostate cancer	0.0407	0.349	CbGbCtD
Valrubicin—TOP2A—Epirubicin—prostate cancer	0.033	0.282	CbGbCtD
Valrubicin—Idarubicin—Epirubicin—prostate cancer	0.0323	0.173	CrCrCtD
Valrubicin—Daunorubicin—Epirubicin—prostate cancer	0.0323	0.173	CrCrCtD
Valrubicin—Doxorubicin—Epirubicin—prostate cancer	0.0323	0.173	CrCrCtD
Valrubicin—Idarubicin—Doxorubicin—prostate cancer	0.0299	0.16	CrCrCtD
Valrubicin—Epirubicin—Doxorubicin—prostate cancer	0.0299	0.16	CrCrCtD
Valrubicin—Daunorubicin—Doxorubicin—prostate cancer	0.0299	0.16	CrCrCtD
Valrubicin—TOP2A—Etoposide—prostate cancer	0.0257	0.22	CbGbCtD
Valrubicin—TOP2A—Doxorubicin—prostate cancer	0.0175	0.15	CbGbCtD
Valrubicin—TOP2A—Docetaxel—Cabazitaxel—prostate cancer	0.000285	0.267	CbGdCrCtD
Valrubicin—Epirubicin—AURKA—prostate cancer	0.000236	0.148	CrCbGaD
Valrubicin—Doxorubicin—CBR1—prostate cancer	0.000226	0.142	CrCbGaD
Valrubicin—TOP2A—Paclitaxel—Cabazitaxel—prostate cancer	0.000197	0.184	CbGdCrCtD
Valrubicin—Doxorubicin—RALBP1—prostate cancer	0.000159	0.0998	CrCbGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—SERPINB10—prostate cancer	0.000156	0.0435	CbGpPWpGaD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—RUNX1—prostate cancer	0.000144	0.0403	CbGpPWpGaD
Valrubicin—Doxorubicin—AURKA—prostate cancer	0.000135	0.0849	CrCbGaD
Valrubicin—Idarubicin—TOP2A—prostate cancer	0.000125	0.0783	CrCbGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—WRN—prostate cancer	0.000118	0.033	CbGpPWpGaD
Valrubicin—TOP2A—Gastric Cancer Network 1—AURKA—prostate cancer	0.000116	0.0325	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—ZFHX3—prostate cancer	0.000113	0.0316	CbGpPWpGaD
Valrubicin—Doxorubicin—AKR1C3—prostate cancer	0.000104	0.065	CrCbGaD
Valrubicin—Epirubicin—TOP2A—prostate cancer	9.47e-05	0.0594	CrCbGaD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—IGFBP3—prostate cancer	9.05e-05	0.0253	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—STMN1—prostate cancer	8.64e-05	0.0241	CbGpPWpGaD
Valrubicin—TOP2A—Paclitaxel—Docetaxel—prostate cancer	8.17e-05	0.0765	CbGdCrCtD
Valrubicin—Doxorubicin—NQO1—prostate cancer	7.78e-05	0.0487	CrCbGaD
Valrubicin—TOP2A—Circadian rythm related genes—NAGLU—prostate cancer	6.86e-05	0.0192	CbGpPWpGaD
Valrubicin—Daunorubicin—TOP2A—prostate cancer	6.7e-05	0.042	CrCbGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—PRKDC—prostate cancer	6.67e-05	0.0187	CbGpPWpGaD
Valrubicin—Daunorubicin—CYP1B1—prostate cancer	6.64e-05	0.0416	CrCbGaD
Valrubicin—Doxorubicin—NOS3—prostate cancer	6.57e-05	0.0411	CrCbGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CD82—prostate cancer	6.46e-05	0.0181	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—ID3—prostate cancer	6.2e-05	0.0173	CbGpPWpGaD
Valrubicin—TOP2A—Gastric Cancer Network 1—APC—prostate cancer	6.15e-05	0.0172	CbGpPWpGaD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—prostate cancer	5.99e-05	0.0167	CbGpPWpGaD
Valrubicin—TOP2A—Fulvestrant—Estradiol—prostate cancer	5.96e-05	0.0558	CbGdCrCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—VDR—prostate cancer	5.79e-05	0.0162	CbGpPWpGaD
Valrubicin—Doxorubicin—TOP2A—prostate cancer	5.44e-05	0.0341	CrCbGaD
Valrubicin—Doxorubicin—CYP1B1—prostate cancer	5.39e-05	0.0338	CrCbGaD
Valrubicin—Daunorubicin—CYP3A5—prostate cancer	5.29e-05	0.0331	CrCbGaD
Valrubicin—TOP2A—Podofilox—Etoposide—prostate cancer	5.25e-05	0.0491	CbGdCrCtD
Valrubicin—TOP2A—Teniposide—Etoposide—prostate cancer	5.25e-05	0.0491	CbGdCrCtD
Valrubicin—TOP2A—Levorphanol—Estrone—prostate cancer	5.2e-05	0.0487	CbGdCrCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—DAG1—prostate cancer	5.13e-05	0.0143	CbGpPWpGaD
Valrubicin—Discomfort—Goserelin—prostate cancer	5.11e-05	0.00141	CcSEcCtD
Valrubicin—Pruritus—Bicalutamide—prostate cancer	5.05e-05	0.00139	CcSEcCtD
Valrubicin—Vasodilation—Doxorubicin—prostate cancer	5.04e-05	0.00139	CcSEcCtD
Valrubicin—Vasodilation procedure—Doxorubicin—prostate cancer	5.04e-05	0.00139	CcSEcCtD
Valrubicin—Feeling abnormal—Ethinyl Estradiol—prostate cancer	4.97e-05	0.00137	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—DNMT1—prostate cancer	4.96e-05	0.0139	CbGpPWpGaD
Valrubicin—Nausea—Cabazitaxel—prostate cancer	4.94e-05	0.00136	CcSEcCtD
Valrubicin—Gastrointestinal pain—Ethinyl Estradiol—prostate cancer	4.93e-05	0.00136	CcSEcCtD
Valrubicin—Diarrhoea—Bicalutamide—prostate cancer	4.88e-05	0.00134	CcSEcCtD
Valrubicin—Pneumonia—Etoposide—prostate cancer	4.81e-05	0.00132	CcSEcCtD
Valrubicin—Nocturia—Doxorubicin—prostate cancer	4.78e-05	0.00132	CcSEcCtD
Valrubicin—Abdominal pain—Ethinyl Estradiol—prostate cancer	4.77e-05	0.00131	CcSEcCtD
Valrubicin—Body temperature increased—Ethinyl Estradiol—prostate cancer	4.77e-05	0.00131	CcSEcCtD
Valrubicin—Irritability—Capecitabine—prostate cancer	4.76e-05	0.00131	CcSEcCtD
Valrubicin—Flatulence—Estradiol—prostate cancer	4.75e-05	0.00131	CcSEcCtD
Valrubicin—Urinary retention—Capecitabine—prostate cancer	4.75e-05	0.00131	CcSEcCtD
Valrubicin—Dizziness—Bicalutamide—prostate cancer	4.72e-05	0.0013	CcSEcCtD
Valrubicin—Cystitis noninfective—Epirubicin—prostate cancer	4.68e-05	0.00129	CcSEcCtD
Valrubicin—Back pain—Estradiol—prostate cancer	4.66e-05	0.00128	CcSEcCtD
Valrubicin—Cystitis—Epirubicin—prostate cancer	4.63e-05	0.00127	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—STMN1—prostate cancer	4.6e-05	0.0129	CbGpPWpGaD
Valrubicin—Vomiting—Bicalutamide—prostate cancer	4.54e-05	0.00125	CcSEcCtD
Valrubicin—Blood urea increased—Epirubicin—prostate cancer	4.52e-05	0.00125	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Goserelin—prostate cancer	4.52e-05	0.00125	CcSEcCtD
Valrubicin—Rash—Bicalutamide—prostate cancer	4.5e-05	0.00124	CcSEcCtD
Valrubicin—Dermatitis—Bicalutamide—prostate cancer	4.49e-05	0.00124	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Conjugated Estrogens—prostate cancer	4.48e-05	0.00123	CcSEcCtD
Valrubicin—Ill-defined disorder—Estradiol—prostate cancer	4.47e-05	0.00123	CcSEcCtD
Valrubicin—Headache—Bicalutamide—prostate cancer	4.47e-05	0.00123	CcSEcCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—ATM—prostate cancer	4.46e-05	0.0125	CbGpPWpGaD
Valrubicin—Malaise—Estradiol—prostate cancer	4.35e-05	0.0012	CcSEcCtD
Valrubicin—Back pain—Mitoxantrone—prostate cancer	4.34e-05	0.0012	CcSEcCtD
Valrubicin—Bladder pain—Epirubicin—prostate cancer	4.33e-05	0.00119	CcSEcCtD
Valrubicin—Cystitis noninfective—Doxorubicin—prostate cancer	4.33e-05	0.00119	CcSEcCtD
Valrubicin—Asthenia—Ethinyl Estradiol—prostate cancer	4.33e-05	0.00119	CcSEcCtD
Valrubicin—Cystitis—Doxorubicin—prostate cancer	4.28e-05	0.00118	CcSEcCtD
Valrubicin—Pruritus—Ethinyl Estradiol—prostate cancer	4.27e-05	0.00118	CcSEcCtD
Valrubicin—Irritability—Prednisone—prostate cancer	4.24e-05	0.00117	CcSEcCtD
Valrubicin—Nausea—Bicalutamide—prostate cancer	4.24e-05	0.00117	CcSEcCtD
Valrubicin—Blood urea increased—Doxorubicin—prostate cancer	4.18e-05	0.00115	CcSEcCtD
Valrubicin—Ill-defined disorder—Mitoxantrone—prostate cancer	4.17e-05	0.00115	CcSEcCtD
Valrubicin—Anaemia—Mitoxantrone—prostate cancer	4.15e-05	0.00114	CcSEcCtD
Valrubicin—Diarrhoea—Ethinyl Estradiol—prostate cancer	4.13e-05	0.00114	CcSEcCtD
Valrubicin—Myalgia—Estradiol—prostate cancer	4.1e-05	0.00113	CcSEcCtD
Valrubicin—Chest pain—Estradiol—prostate cancer	4.1e-05	0.00113	CcSEcCtD
Valrubicin—Feeling abnormal—Goserelin—prostate cancer	4.09e-05	0.00113	CcSEcCtD
Valrubicin—Gastrointestinal pain—Goserelin—prostate cancer	4.06e-05	0.00112	CcSEcCtD
Valrubicin—Discomfort—Estradiol—prostate cancer	4.05e-05	0.00112	CcSEcCtD
Valrubicin—Malaise—Mitoxantrone—prostate cancer	4.05e-05	0.00112	CcSEcCtD
Valrubicin—Dysuria—Capecitabine—prostate cancer	4.03e-05	0.00111	CcSEcCtD
Valrubicin—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	4.02e-05	0.00111	CcSEcCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—GSK3B—prostate cancer	4.01e-05	0.0112	CbGpPWpGaD
Valrubicin—Bladder pain—Doxorubicin—prostate cancer	4.01e-05	0.0011	CcSEcCtD
Valrubicin—Pneumonia—Docetaxel—prostate cancer	4e-05	0.0011	CcSEcCtD
Valrubicin—Dizziness—Ethinyl Estradiol—prostate cancer	3.99e-05	0.0011	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 2—CTNNB1—prostate cancer	3.96e-05	0.0111	CbGpPWpGaD
Valrubicin—TOP2A—Levorphanol—Estradiol—prostate cancer	3.94e-05	0.0369	CbGdCrCtD
Valrubicin—Abdominal pain—Goserelin—prostate cancer	3.92e-05	0.00108	CcSEcCtD
Valrubicin—Body temperature increased—Goserelin—prostate cancer	3.92e-05	0.00108	CcSEcCtD
Valrubicin—Hyperglycaemia—Capecitabine—prostate cancer	3.89e-05	0.00107	CcSEcCtD
Valrubicin—Abdominal pain—Conjugated Estrogens—prostate cancer	3.89e-05	0.00107	CcSEcCtD
Valrubicin—Body temperature increased—Conjugated Estrogens—prostate cancer	3.89e-05	0.00107	CcSEcCtD
Valrubicin—Pneumonia—Capecitabine—prostate cancer	3.87e-05	0.00107	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle—PSMC3IP—prostate cancer	3.87e-05	0.0108	CbGpPWpGaD
Valrubicin—Vomiting—Ethinyl Estradiol—prostate cancer	3.83e-05	0.00106	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—HNF1B—prostate cancer	3.83e-05	0.0107	CbGpPWpGaD
Valrubicin—Myalgia—Mitoxantrone—prostate cancer	3.82e-05	0.00105	CcSEcCtD
Valrubicin—Chest pain—Mitoxantrone—prostate cancer	3.82e-05	0.00105	CcSEcCtD
Valrubicin—Rash—Ethinyl Estradiol—prostate cancer	3.8e-05	0.00105	CcSEcCtD
Valrubicin—Dermatitis—Ethinyl Estradiol—prostate cancer	3.8e-05	0.00105	CcSEcCtD
Valrubicin—Discomfort—Mitoxantrone—prostate cancer	3.78e-05	0.00104	CcSEcCtD
Valrubicin—Headache—Ethinyl Estradiol—prostate cancer	3.78e-05	0.00104	CcSEcCtD
Valrubicin—Urinary tract infection—Capecitabine—prostate cancer	3.74e-05	0.00103	CcSEcCtD
Valrubicin—Haematuria—Capecitabine—prostate cancer	3.67e-05	0.00101	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—HSP90AB1—prostate cancer	3.63e-05	0.0101	CbGpPWpGaD
Valrubicin—Back pain—Etoposide—prostate cancer	3.61e-05	0.000996	CcSEcCtD
Valrubicin—TOP2A—Methyltestosterone—Ethinyl Estradiol—prostate cancer	3.6e-05	0.0337	CbGdCrCtD
Valrubicin—Daunorubicin—CYP1A1—prostate cancer	3.59e-05	0.0225	CrCbGaD
Valrubicin—Musculoskeletal discomfort—Estradiol—prostate cancer	3.58e-05	0.000988	CcSEcCtD
Valrubicin—Nausea—Ethinyl Estradiol—prostate cancer	3.58e-05	0.000987	CcSEcCtD
Valrubicin—Asthenia—Goserelin—prostate cancer	3.56e-05	0.000981	CcSEcCtD
Valrubicin—Asthenia—Conjugated Estrogens—prostate cancer	3.53e-05	0.000972	CcSEcCtD
Valrubicin—Oedema peripheral—Docetaxel—prostate cancer	3.51e-05	0.000968	CcSEcCtD
Valrubicin—Pruritus—Goserelin—prostate cancer	3.51e-05	0.000967	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EIF2AK2—prostate cancer	3.49e-05	0.00975	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—TYMS—prostate cancer	3.48e-05	0.00972	CbGpPWpGaD
Valrubicin—Pruritus—Conjugated Estrogens—prostate cancer	3.48e-05	0.000958	CcSEcCtD
Valrubicin—Hyperglycaemia—Prednisone—prostate cancer	3.47e-05	0.000955	CcSEcCtD
Valrubicin—Ill-defined disorder—Etoposide—prostate cancer	3.47e-05	0.000955	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle, Mitotic—PCNT—prostate cancer	3.46e-05	0.00967	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—USO1—prostate cancer	3.46e-05	0.00967	CbGpPWpGaD
Valrubicin—Anaemia—Etoposide—prostate cancer	3.45e-05	0.000951	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—PRKDC—prostate cancer	3.42e-05	0.00955	CbGpPWpGaD
Valrubicin—Oedema peripheral—Capecitabine—prostate cancer	3.4e-05	0.000937	CcSEcCtD
Valrubicin—Diarrhoea—Goserelin—prostate cancer	3.4e-05	0.000936	CcSEcCtD
Valrubicin—Malaise—Etoposide—prostate cancer	3.37e-05	0.000928	CcSEcCtD
Valrubicin—Diarrhoea—Conjugated Estrogens—prostate cancer	3.36e-05	0.000927	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	3.34e-05	0.00092	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—prostate cancer	3.31e-05	0.00924	CbGpPWpGaD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—prostate cancer	3.29e-05	0.0092	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—REC8—prostate cancer	3.29e-05	0.00919	CbGpPWpGaD
Valrubicin—Dizziness—Goserelin—prostate cancer	3.28e-05	0.000904	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—AHR—prostate cancer	3.26e-05	0.00911	CbGpPWpGaD
Valrubicin—Dizziness—Conjugated Estrogens—prostate cancer	3.25e-05	0.000896	CcSEcCtD
Valrubicin—Feeling abnormal—Estradiol—prostate cancer	3.24e-05	0.000893	CcSEcCtD
Valrubicin—Gastrointestinal pain—Estradiol—prostate cancer	3.22e-05	0.000886	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 2—MYC—prostate cancer	3.21e-05	0.00896	CbGpPWpGaD
Valrubicin—Chest pain—Etoposide—prostate cancer	3.18e-05	0.000876	CcSEcCtD
Valrubicin—Vomiting—Goserelin—prostate cancer	3.16e-05	0.000869	CcSEcCtD
Valrubicin—Discomfort—Etoposide—prostate cancer	3.14e-05	0.000866	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 2—EGFR—prostate cancer	3.14e-05	0.00877	CbGpPWpGaD
Valrubicin—Rash—Goserelin—prostate cancer	3.13e-05	0.000862	CcSEcCtD
Valrubicin—Dermatitis—Goserelin—prostate cancer	3.13e-05	0.000861	CcSEcCtD
Valrubicin—Vomiting—Conjugated Estrogens—prostate cancer	3.13e-05	0.000861	CcSEcCtD
Valrubicin—Body temperature increased—Estradiol—prostate cancer	3.11e-05	0.000857	CcSEcCtD
Valrubicin—Abdominal pain—Estradiol—prostate cancer	3.11e-05	0.000857	CcSEcCtD
Valrubicin—Headache—Goserelin—prostate cancer	3.11e-05	0.000857	CcSEcCtD
Valrubicin—Rash—Conjugated Estrogens—prostate cancer	3.1e-05	0.000854	CcSEcCtD
Valrubicin—Dermatitis—Conjugated Estrogens—prostate cancer	3.1e-05	0.000853	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle—USO1—prostate cancer	3.09e-05	0.00864	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—PCNT—prostate cancer	3.09e-05	0.00864	CbGpPWpGaD
Valrubicin—Headache—Conjugated Estrogens—prostate cancer	3.08e-05	0.000849	CcSEcCtD
Valrubicin—Feeling abnormal—Mitoxantrone—prostate cancer	3.02e-05	0.000832	CcSEcCtD
Valrubicin—Back pain—Docetaxel—prostate cancer	3e-05	0.000828	CcSEcCtD
Valrubicin—Gastrointestinal pain—Mitoxantrone—prostate cancer	3e-05	0.000826	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—HPGDS—prostate cancer	2.97e-05	0.00829	CbGpPWpGaD
Valrubicin—Flatulence—Capecitabine—prostate cancer	2.96e-05	0.000816	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—IGFBP3—prostate cancer	2.95e-05	0.00824	CbGpPWpGaD
Valrubicin—Nausea—Goserelin—prostate cancer	2.95e-05	0.000812	CcSEcCtD
Valrubicin—Nausea—Conjugated Estrogens—prostate cancer	2.92e-05	0.000805	CcSEcCtD
Valrubicin—Back pain—Capecitabine—prostate cancer	2.91e-05	0.000801	CcSEcCtD
Valrubicin—Body temperature increased—Mitoxantrone—prostate cancer	2.9e-05	0.000798	CcSEcCtD
Valrubicin—Abdominal pain—Mitoxantrone—prostate cancer	2.9e-05	0.000798	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ACHE—prostate cancer	2.88e-05	0.00804	CbGpPWpGaD
Valrubicin—Anaemia—Docetaxel—prostate cancer	2.87e-05	0.000791	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CCND2—prostate cancer	2.85e-05	0.00795	CbGpPWpGaD
Valrubicin—Asthenia—Estradiol—prostate cancer	2.82e-05	0.000778	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TGFBR1—prostate cancer	2.81e-05	0.00786	CbGpPWpGaD
Valrubicin—Dysuria—Epirubicin—prostate cancer	2.81e-05	0.000774	CcSEcCtD
Valrubicin—Ill-defined disorder—Capecitabine—prostate cancer	2.79e-05	0.000769	CcSEcCtD
Valrubicin—Pruritus—Estradiol—prostate cancer	2.78e-05	0.000767	CcSEcCtD
Valrubicin—Anaemia—Capecitabine—prostate cancer	2.78e-05	0.000766	CcSEcCtD
Valrubicin—Pollakiuria—Epirubicin—prostate cancer	2.78e-05	0.000765	CcSEcCtD
Valrubicin—TOP2A—Idarubicin—Epirubicin—prostate cancer	2.74e-05	0.0256	CbGdCrCtD
Valrubicin—TOP2A—Doxorubicin—Epirubicin—prostate cancer	2.74e-05	0.0256	CbGdCrCtD
Valrubicin—TOP2A—Daunorubicin—Epirubicin—prostate cancer	2.74e-05	0.0256	CbGdCrCtD
Valrubicin—Hyperglycaemia—Epirubicin—prostate cancer	2.71e-05	0.000747	CcSEcCtD
Valrubicin—Malaise—Capecitabine—prostate cancer	2.71e-05	0.000747	CcSEcCtD
Valrubicin—Pneumonia—Epirubicin—prostate cancer	2.7e-05	0.000743	CcSEcCtD
Valrubicin—Diarrhoea—Estradiol—prostate cancer	2.69e-05	0.000742	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—THBS1—prostate cancer	2.68e-05	0.0075	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ANXA1—prostate cancer	2.64e-05	0.00739	CbGpPWpGaD
Valrubicin—Chest pain—Docetaxel—prostate cancer	2.64e-05	0.000728	CcSEcCtD
Valrubicin—Myalgia—Docetaxel—prostate cancer	2.64e-05	0.000728	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 2—TP53—prostate cancer	2.63e-05	0.00736	CbGpPWpGaD
Valrubicin—Asthenia—Mitoxantrone—prostate cancer	2.63e-05	0.000725	CcSEcCtD
Valrubicin—Urinary tract infection—Epirubicin—prostate cancer	2.6e-05	0.000718	CcSEcCtD
Valrubicin—Dizziness—Estradiol—prostate cancer	2.6e-05	0.000717	CcSEcCtD
Valrubicin—Dysuria—Doxorubicin—prostate cancer	2.6e-05	0.000717	CcSEcCtD
Valrubicin—Pollakiuria—Doxorubicin—prostate cancer	2.57e-05	0.000708	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EZH2—prostate cancer	2.56e-05	0.00716	CbGpPWpGaD
Valrubicin—Chest pain—Capecitabine—prostate cancer	2.56e-05	0.000705	CcSEcCtD
Valrubicin—Myalgia—Capecitabine—prostate cancer	2.56e-05	0.000705	CcSEcCtD
Valrubicin—Haematuria—Epirubicin—prostate cancer	2.56e-05	0.000704	CcSEcCtD
Valrubicin—TOP2A—Idarubicin—Doxorubicin—prostate cancer	2.53e-05	0.0237	CbGdCrCtD
Valrubicin—TOP2A—Epirubicin—Doxorubicin—prostate cancer	2.53e-05	0.0237	CbGdCrCtD
Valrubicin—TOP2A—Daunorubicin—Doxorubicin—prostate cancer	2.53e-05	0.0237	CbGdCrCtD
Valrubicin—Discomfort—Capecitabine—prostate cancer	2.53e-05	0.000697	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—GADD45A—prostate cancer	2.52e-05	0.00703	CbGpPWpGaD
Valrubicin—Feeling abnormal—Etoposide—prostate cancer	2.51e-05	0.000692	CcSEcCtD
Valrubicin—Hyperglycaemia—Doxorubicin—prostate cancer	2.51e-05	0.000691	CcSEcCtD
Valrubicin—Diarrhoea—Mitoxantrone—prostate cancer	2.51e-05	0.000691	CcSEcCtD
Valrubicin—Vomiting—Estradiol—prostate cancer	2.5e-05	0.000689	CcSEcCtD
Valrubicin—Pneumonia—Doxorubicin—prostate cancer	2.49e-05	0.000687	CcSEcCtD
Valrubicin—Gastrointestinal pain—Etoposide—prostate cancer	2.49e-05	0.000687	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—NCOA2—prostate cancer	2.49e-05	0.00696	CbGpPWpGaD
Valrubicin—Ill-defined disorder—Prednisone—prostate cancer	2.48e-05	0.000685	CcSEcCtD
Valrubicin—Rash—Estradiol—prostate cancer	2.48e-05	0.000683	CcSEcCtD
Valrubicin—Dermatitis—Estradiol—prostate cancer	2.48e-05	0.000683	CcSEcCtD
Valrubicin—Anaemia—Prednisone—prostate cancer	2.47e-05	0.000682	CcSEcCtD
Valrubicin—Headache—Estradiol—prostate cancer	2.46e-05	0.000679	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—EZH2—prostate cancer	2.46e-05	0.00687	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—TYMS—prostate cancer	2.45e-05	0.00684	CbGpPWpGaD
Valrubicin—Malaise—Prednisone—prostate cancer	2.41e-05	0.000665	CcSEcCtD
Valrubicin—Abdominal pain—Etoposide—prostate cancer	2.41e-05	0.000664	CcSEcCtD
Valrubicin—Body temperature increased—Etoposide—prostate cancer	2.41e-05	0.000664	CcSEcCtD
Valrubicin—Urinary tract infection—Doxorubicin—prostate cancer	2.41e-05	0.000664	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR2—prostate cancer	2.37e-05	0.00663	CbGpPWpGaD
Valrubicin—Oedema peripheral—Epirubicin—prostate cancer	2.37e-05	0.000653	CcSEcCtD
Valrubicin—Haematuria—Doxorubicin—prostate cancer	2.36e-05	0.000651	CcSEcCtD
Valrubicin—TOP2A—Norethindrone—Ethinyl Estradiol—prostate cancer	2.34e-05	0.0219	CbGdCrCtD
Valrubicin—Nausea—Estradiol—prostate cancer	2.34e-05	0.000644	CcSEcCtD
Valrubicin—Vomiting—Mitoxantrone—prostate cancer	2.33e-05	0.000642	CcSEcCtD
Valrubicin—Rash—Mitoxantrone—prostate cancer	2.31e-05	0.000637	CcSEcCtD
Valrubicin—Dermatitis—Mitoxantrone—prostate cancer	2.31e-05	0.000636	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Docetaxel—prostate cancer	2.31e-05	0.000636	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CHEK2—prostate cancer	2.3e-05	0.00643	CbGpPWpGaD
Valrubicin—Headache—Mitoxantrone—prostate cancer	2.3e-05	0.000633	CcSEcCtD
Valrubicin—Daunorubicin—CYP3A4—prostate cancer	2.29e-05	0.0143	CrCbGaD
Valrubicin—Myalgia—Prednisone—prostate cancer	2.28e-05	0.000628	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CASP9—prostate cancer	2.28e-05	0.00636	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—TH—prostate cancer	2.26e-05	0.00632	CbGpPWpGaD
Valrubicin—Discomfort—Prednisone—prostate cancer	2.25e-05	0.000621	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Capecitabine—prostate cancer	2.24e-05	0.000616	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGR1—prostate cancer	2.22e-05	0.00621	CbGpPWpGaD
Valrubicin—Oedema peripheral—Doxorubicin—prostate cancer	2.19e-05	0.000604	CcSEcCtD
Valrubicin—Asthenia—Etoposide—prostate cancer	2.19e-05	0.000603	CcSEcCtD
Valrubicin—Nausea—Mitoxantrone—prostate cancer	2.18e-05	0.0006	CcSEcCtD
Valrubicin—Pruritus—Etoposide—prostate cancer	2.16e-05	0.000594	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA1—prostate cancer	2.16e-05	0.00602	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—EGR1—prostate cancer	2.13e-05	0.00596	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—NGFR—prostate cancer	2.12e-05	0.00592	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—AR—prostate cancer	2.1e-05	0.00586	CbGpPWpGaD
Valrubicin—Feeling abnormal—Docetaxel—prostate cancer	2.09e-05	0.000575	CcSEcCtD
Valrubicin—Diarrhoea—Etoposide—prostate cancer	2.09e-05	0.000575	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—RXRA—prostate cancer	2.08e-05	0.00581	CbGpPWpGaD
Valrubicin—Gastrointestinal pain—Docetaxel—prostate cancer	2.07e-05	0.000571	CcSEcCtD
Valrubicin—Flatulence—Epirubicin—prostate cancer	2.06e-05	0.000569	CcSEcCtD
Valrubicin—Back pain—Epirubicin—prostate cancer	2.03e-05	0.000558	CcSEcCtD
Valrubicin—Feeling abnormal—Capecitabine—prostate cancer	2.02e-05	0.000557	CcSEcCtD
Valrubicin—Dizziness—Etoposide—prostate cancer	2.02e-05	0.000556	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—prostate cancer	2.01e-05	0.00562	CbGpPWpGaD
Valrubicin—Gastrointestinal pain—Capecitabine—prostate cancer	2.01e-05	0.000553	CcSEcCtD
Valrubicin—Abdominal pain—Docetaxel—prostate cancer	2e-05	0.000552	CcSEcCtD
Valrubicin—Body temperature increased—Docetaxel—prostate cancer	2e-05	0.000552	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Prednisone—prostate cancer	1.99e-05	0.000549	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA2—prostate cancer	1.95e-05	0.00545	CbGpPWpGaD
Valrubicin—Ill-defined disorder—Epirubicin—prostate cancer	1.94e-05	0.000535	CcSEcCtD
Valrubicin—Body temperature increased—Capecitabine—prostate cancer	1.94e-05	0.000534	CcSEcCtD
Valrubicin—Abdominal pain—Capecitabine—prostate cancer	1.94e-05	0.000534	CcSEcCtD
Valrubicin—Vomiting—Etoposide—prostate cancer	1.94e-05	0.000534	CcSEcCtD
Valrubicin—Anaemia—Epirubicin—prostate cancer	1.94e-05	0.000533	CcSEcCtD
Valrubicin—Rash—Etoposide—prostate cancer	1.92e-05	0.00053	CcSEcCtD
Valrubicin—Dermatitis—Etoposide—prostate cancer	1.92e-05	0.000529	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—SIRT1—prostate cancer	1.91e-05	0.00534	CbGpPWpGaD
Valrubicin—Headache—Etoposide—prostate cancer	1.91e-05	0.000526	CcSEcCtD
Valrubicin—Flatulence—Doxorubicin—prostate cancer	1.91e-05	0.000526	CcSEcCtD
Valrubicin—Malaise—Epirubicin—prostate cancer	1.89e-05	0.00052	CcSEcCtD
Valrubicin—Back pain—Doxorubicin—prostate cancer	1.87e-05	0.000516	CcSEcCtD
Valrubicin—TOP2A—Levonorgestrel—Ethinyl Estradiol—prostate cancer	1.87e-05	0.0175	CbGdCrCtD
Valrubicin—Doxorubicin—CYP3A4—prostate cancer	1.86e-05	0.0116	CrCbGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—prostate cancer	1.85e-05	0.00518	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1B—prostate cancer	1.84e-05	0.00513	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—SIRT1—prostate cancer	1.84e-05	0.00513	CbGpPWpGaD
Valrubicin—Asthenia—Docetaxel—prostate cancer	1.82e-05	0.000501	CcSEcCtD
Valrubicin—Nausea—Etoposide—prostate cancer	1.81e-05	0.000499	CcSEcCtD
Valrubicin—Feeling abnormal—Prednisone—prostate cancer	1.8e-05	0.000496	CcSEcCtD
Valrubicin—Ill-defined disorder—Doxorubicin—prostate cancer	1.8e-05	0.000495	CcSEcCtD
Valrubicin—Pruritus—Docetaxel—prostate cancer	1.79e-05	0.000494	CcSEcCtD
Valrubicin—Anaemia—Doxorubicin—prostate cancer	1.79e-05	0.000493	CcSEcCtD
Valrubicin—Gastrointestinal pain—Prednisone—prostate cancer	1.79e-05	0.000492	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BAX—prostate cancer	1.79e-05	0.00499	CbGpPWpGaD
Valrubicin—Chest pain—Epirubicin—prostate cancer	1.78e-05	0.000491	CcSEcCtD
Valrubicin—Myalgia—Epirubicin—prostate cancer	1.78e-05	0.000491	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—TYMS—prostate cancer	1.78e-05	0.00497	CbGpPWpGaD
Valrubicin—Discomfort—Epirubicin—prostate cancer	1.76e-05	0.000485	CcSEcCtD
Valrubicin—Asthenia—Capecitabine—prostate cancer	1.76e-05	0.000485	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—prostate cancer	1.75e-05	0.00489	CbGpPWpGaD
Valrubicin—Malaise—Doxorubicin—prostate cancer	1.75e-05	0.000481	CcSEcCtD
Valrubicin—Pruritus—Capecitabine—prostate cancer	1.74e-05	0.000478	CcSEcCtD
Valrubicin—Diarrhoea—Docetaxel—prostate cancer	1.73e-05	0.000478	CcSEcCtD
Valrubicin—Abdominal pain—Prednisone—prostate cancer	1.73e-05	0.000476	CcSEcCtD
Valrubicin—Body temperature increased—Prednisone—prostate cancer	1.73e-05	0.000476	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—FASLG—prostate cancer	1.7e-05	0.00476	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—prostate cancer	1.69e-05	0.00473	CbGpPWpGaD
Valrubicin—Diarrhoea—Capecitabine—prostate cancer	1.68e-05	0.000463	CcSEcCtD
Valrubicin—Dizziness—Docetaxel—prostate cancer	1.68e-05	0.000462	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle, Mitotic—HIST1H2BG—prostate cancer	1.66e-05	0.00463	CbGpPWpGaD
Valrubicin—Chest pain—Doxorubicin—prostate cancer	1.65e-05	0.000455	CcSEcCtD
Valrubicin—Myalgia—Doxorubicin—prostate cancer	1.65e-05	0.000455	CcSEcCtD
Valrubicin—Discomfort—Doxorubicin—prostate cancer	1.63e-05	0.000449	CcSEcCtD
Valrubicin—Dizziness—Capecitabine—prostate cancer	1.62e-05	0.000447	CcSEcCtD
Valrubicin—Vomiting—Docetaxel—prostate cancer	1.61e-05	0.000444	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle, Mitotic—HIST1H4H—prostate cancer	1.6e-05	0.00447	CbGpPWpGaD
Valrubicin—Rash—Docetaxel—prostate cancer	1.6e-05	0.00044	CcSEcCtD
Valrubicin—Dermatitis—Docetaxel—prostate cancer	1.6e-05	0.00044	CcSEcCtD
Valrubicin—Headache—Docetaxel—prostate cancer	1.59e-05	0.000437	CcSEcCtD
Valrubicin—Asthenia—Prednisone—prostate cancer	1.57e-05	0.000432	CcSEcCtD
Valrubicin—Vomiting—Capecitabine—prostate cancer	1.56e-05	0.00043	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.56e-05	0.000429	CcSEcCtD
Valrubicin—Rash—Capecitabine—prostate cancer	1.55e-05	0.000426	CcSEcCtD
Valrubicin—Pruritus—Prednisone—prostate cancer	1.55e-05	0.000426	CcSEcCtD
Valrubicin—Dermatitis—Capecitabine—prostate cancer	1.55e-05	0.000426	CcSEcCtD
Valrubicin—Headache—Capecitabine—prostate cancer	1.54e-05	0.000423	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—PPARA—prostate cancer	1.53e-05	0.00426	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—MAD1L1—prostate cancer	1.51e-05	0.00421	CbGpPWpGaD
Valrubicin—Nausea—Docetaxel—prostate cancer	1.51e-05	0.000415	CcSEcCtD
Valrubicin—Diarrhoea—Prednisone—prostate cancer	1.5e-05	0.000412	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle—HIST1H2BG—prostate cancer	1.48e-05	0.00414	CbGpPWpGaD
Valrubicin—Nausea—Capecitabine—prostate cancer	1.46e-05	0.000402	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ATM—prostate cancer	1.45e-05	0.00406	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—LEP—prostate cancer	1.45e-05	0.00405	CbGpPWpGaD
Valrubicin—Dizziness—Prednisone—prostate cancer	1.45e-05	0.000398	CcSEcCtD
Valrubicin—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.44e-05	0.000397	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—prostate cancer	1.44e-05	0.00402	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—HIST1H4H—prostate cancer	1.43e-05	0.004	CbGpPWpGaD
Valrubicin—Feeling abnormal—Epirubicin—prostate cancer	1.41e-05	0.000388	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BAD—prostate cancer	1.41e-05	0.00393	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—prostate cancer	1.4e-05	0.00393	CbGpPWpGaD
Valrubicin—Gastrointestinal pain—Epirubicin—prostate cancer	1.4e-05	0.000385	CcSEcCtD
Valrubicin—Vomiting—Prednisone—prostate cancer	1.39e-05	0.000383	CcSEcCtD
Valrubicin—Rash—Prednisone—prostate cancer	1.38e-05	0.00038	CcSEcCtD
Valrubicin—Dermatitis—Prednisone—prostate cancer	1.38e-05	0.000379	CcSEcCtD
Valrubicin—Headache—Prednisone—prostate cancer	1.37e-05	0.000377	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—APC—prostate cancer	1.36e-05	0.0038	CbGpPWpGaD
Valrubicin—Body temperature increased—Epirubicin—prostate cancer	1.35e-05	0.000372	CcSEcCtD
Valrubicin—Abdominal pain—Epirubicin—prostate cancer	1.35e-05	0.000372	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle—MAD1L1—prostate cancer	1.35e-05	0.00376	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGF—prostate cancer	1.35e-05	0.00376	CbGpPWpGaD
Valrubicin—Feeling abnormal—Doxorubicin—prostate cancer	1.3e-05	0.000359	CcSEcCtD
Valrubicin—Nausea—Prednisone—prostate cancer	1.3e-05	0.000358	CcSEcCtD
Valrubicin—Gastrointestinal pain—Doxorubicin—prostate cancer	1.29e-05	0.000356	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDKN1B—prostate cancer	1.29e-05	0.00361	CbGpPWpGaD
Valrubicin—TOP2A—Methyltestosterone—Prednisone—prostate cancer	1.26e-05	0.0118	CbGdCrCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CREBBP—prostate cancer	1.26e-05	0.00353	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—GSK3B—prostate cancer	1.25e-05	0.0035	CbGpPWpGaD
Valrubicin—Abdominal pain—Doxorubicin—prostate cancer	1.25e-05	0.000344	CcSEcCtD
Valrubicin—Body temperature increased—Doxorubicin—prostate cancer	1.25e-05	0.000344	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—IGF1—prostate cancer	1.25e-05	0.00348	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—AURKA—prostate cancer	1.25e-05	0.00348	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—NBN—prostate cancer	1.24e-05	0.00346	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CCND1—prostate cancer	1.23e-05	0.00344	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—MLH1—prostate cancer	1.23e-05	0.00344	CbGpPWpGaD
Valrubicin—Asthenia—Epirubicin—prostate cancer	1.23e-05	0.000338	CcSEcCtD
Valrubicin—Pruritus—Epirubicin—prostate cancer	1.21e-05	0.000333	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MAP2K1—prostate cancer	1.2e-05	0.00337	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDKN1A—prostate cancer	1.19e-05	0.00333	CbGpPWpGaD
Valrubicin—Diarrhoea—Epirubicin—prostate cancer	1.17e-05	0.000322	CcSEcCtD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—prostate cancer	1.15e-05	0.00322	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—FGF2—prostate cancer	1.15e-05	0.0032	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—SERPINE1—prostate cancer	1.14e-05	0.00317	CbGpPWpGaD
Valrubicin—Asthenia—Doxorubicin—prostate cancer	1.13e-05	0.000313	CcSEcCtD
Valrubicin—Dizziness—Epirubicin—prostate cancer	1.13e-05	0.000311	CcSEcCtD
Valrubicin—Pruritus—Doxorubicin—prostate cancer	1.12e-05	0.000308	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle—AURKA—prostate cancer	1.11e-05	0.00311	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BCL2—prostate cancer	1.09e-05	0.00304	CbGpPWpGaD
Valrubicin—Vomiting—Epirubicin—prostate cancer	1.09e-05	0.000299	CcSEcCtD
Valrubicin—Diarrhoea—Doxorubicin—prostate cancer	1.08e-05	0.000298	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle, Mitotic—APEX1—prostate cancer	1.08e-05	0.00302	CbGpPWpGaD
Valrubicin—Rash—Epirubicin—prostate cancer	1.08e-05	0.000297	CcSEcCtD
Valrubicin—Dermatitis—Epirubicin—prostate cancer	1.08e-05	0.000297	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—prostate cancer	1.07e-05	0.003	CbGpPWpGaD
Valrubicin—Headache—Epirubicin—prostate cancer	1.07e-05	0.000295	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—prostate cancer	1.06e-05	0.00295	CbGpPWpGaD
Valrubicin—Dizziness—Doxorubicin—prostate cancer	1.05e-05	0.000288	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CCND2—prostate cancer	1.04e-05	0.00292	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—prostate cancer	1.03e-05	0.00289	CbGpPWpGaD
Valrubicin—Nausea—Epirubicin—prostate cancer	1.02e-05	0.00028	CcSEcCtD
Valrubicin—Vomiting—Doxorubicin—prostate cancer	1.01e-05	0.000277	CcSEcCtD
Valrubicin—Rash—Doxorubicin—prostate cancer	9.97e-06	0.000275	CcSEcCtD
Valrubicin—Dermatitis—Doxorubicin—prostate cancer	9.96e-06	0.000274	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle—CHEK2—prostate cancer	9.96e-06	0.00278	CbGpPWpGaD
Valrubicin—Headache—Doxorubicin—prostate cancer	9.91e-06	0.000273	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—MYC—prostate cancer	9.89e-06	0.00276	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—prostate cancer	9.79e-06	0.00273	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—APEX1—prostate cancer	9.67e-06	0.0027	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—prostate cancer	9.59e-06	0.00268	CbGpPWpGaD
Valrubicin—Nausea—Doxorubicin—prostate cancer	9.39e-06	0.000259	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—prostate cancer	9.34e-06	0.00261	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—BRCA1—prostate cancer	9.33e-06	0.00261	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CCND2—prostate cancer	9.33e-06	0.00261	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—prostate cancer	9.25e-06	0.00258	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—prostate cancer	9.03e-06	0.00252	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—prostate cancer	9.01e-06	0.00252	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—TYMS—prostate cancer	8.98e-06	0.00251	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—PTEN—prostate cancer	8.65e-06	0.00242	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—prostate cancer	8.59e-06	0.0024	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—BRCA2—prostate cancer	8.44e-06	0.00236	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—prostate cancer	8.36e-06	0.00234	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—EP300—prostate cancer	8.25e-06	0.00231	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—prostate cancer	8.14e-06	0.00227	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—TYMS—prostate cancer	8.03e-06	0.00224	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—prostate cancer	7.49e-06	0.00209	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TGFB1—prostate cancer	7.47e-06	0.00209	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—prostate cancer	7.33e-06	0.00205	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—TERT—prostate cancer	6.99e-06	0.00195	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—prostate cancer	6.92e-06	0.00193	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	6.36e-06	0.00178	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—ATM—prostate cancer	6.29e-06	0.00176	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	6.15e-06	0.00172	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—TP53—prostate cancer	5.9e-06	0.00165	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—IL6—prostate cancer	5.4e-06	0.00151	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	5.19e-06	0.00145	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDKN1B—prostate cancer	4.74e-06	0.00132	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—MDM2—prostate cancer	4.64e-06	0.0013	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CCND1—prostate cancer	4.52e-06	0.00126	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDKN1A—prostate cancer	4.37e-06	0.00122	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDKN1B—prostate cancer	4.24e-06	0.00118	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—EP300—prostate cancer	4.16e-06	0.00116	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CCND1—prostate cancer	4.04e-06	0.00113	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDKN1A—prostate cancer	3.91e-06	0.00109	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—EP300—prostate cancer	3.72e-06	0.00104	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—MYC—prostate cancer	3.63e-06	0.00101	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—MYC—prostate cancer	3.24e-06	0.000906	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—TP53—prostate cancer	2.66e-06	0.000744	CbGpPWpGaD
